Deuterated colexitinib improves quality of life in patients with moderate to severe psoriasis

Deucravacitinib showed significant results in improving skin-related quality of life in patients with moderate to severe plaque psoriasis, according to research published in 2025. The study results showed that among patients receiving deuterated colexitinib, the proportion of patients with no impact on quality of life increased from 0% at baseline to 33.3% at week 16. At the same time, only 17.5% of patients reported a very large impact on their quality of life at week 16, which was significantly lower than the previous 54.2%. These changes fully reflect the outstanding efficacy of deuterated colexitinib.

According to the National Psoriasis Foundation,40.6% to 43.3% of people with psoriasis report that their quality of life is moderately to very significantly affected, and this impact increases with the severity of the disease. Specifically, as many as 72.4% of patients stated that the disease affected their daily activities, and 29.3% even stated that they were unable to participate in social activities. These statistics highlight the negative impact psoriasis has on patients' quality of life and underscore the importance of finding effective treatments.

The ARTISTYK trial is a randomized, double-blind, placebo-controlled, phase 4 study designed to evaluate the impact of the oral tyrosine kinase 2 inhibitor deuterated colexitinib on quality of life in patients with moderate to severe plaque psoriasis. In this study, 180 psoriasis patients with a BSA (body surface area) greater than 3% were randomly assigned to receive placebo (n=60) or deuterated colexitinib (n=120). The results showed that 70% of patients reported at baseline that the disease had a "very large impact" on their quality of life, with a DLQI (Dermatology Life Quality Index) score of 11 or higher, demonstrating the distress the disease caused to patients.

After 16 weeks of treatment, 33.3% of patients in the deuterocelexitinib group reported that psoriasis had no impact on their quality of life. This significant improvement is noteworthy. Additionally, there was a significant decrease in the proportion of patients reporting a large impact on quality of life, further supporting the effectiveness of deuterated colexitinib. Patients who received deuterated colexitinib were more likely to have better DLQI scores compared with those who received placebo, with an odds ratio of 3.195 (95% CI, 1.8-5.5).

In addition, the improvement rate of systemic itch in the deuterated colexitinib group was also significantly higher than that in the placebo group, which was 51.8% (95% CI, 42.1%-61.3%) and 27.8% (95% CI, 16.5%-41.6%) respectively. These data further demonstrate that colexitinib not only improves skin symptoms but also has a positive impact on patients' overall quality of life.

Across multiple assessment categories, there were significant improvements in diary scores of signs and symptoms of psoriasis in the deuterated colexitinib group compared with the placebo group. For example, the symptom score improvement was -27.6 (95% CI, -31.6 to -23.6, vs. -10.8 in the placebo group; 95% CI, -16.4 to -5.2), and the sign improvement was -29.1 (95% CI, -33.2 to -25.1, vs. placebo -10.8 in the placebo group; 95% CI, -16.5 to -5.1) and an improvement in overall disease performance of -28.4 (95% CI, -32.3 to -24.4, compared with -10.8 in the placebo group; 95% CI, -16.4 to -5.2), all of which were statistically significant (P<0.0001).

These results suggest that the impact of psoriasis on quality of life is not entirely dependent on disease severity. He noted that even patients with smaller body surface areas can be negatively affected by the disease, so appropriate treatment strategies should be based on the patient's individual needs, not just the severity of the disease.

Reference: https://www.healio.com/news/dermatology/20250128/deucravacitinib-improves-quality-of-life-of-patients-with-moderate-severe-psoriasis